BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 6637851)

  • 1. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
    Morady F; Sauve MJ; Malone P; Shen EN; Schwartz AB; Bhandari A; Keung E; Sung RJ; Scheinman MM
    Am J Cardiol; 1983 Nov; 52(8):975-9. PubMed ID: 6637851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation.
    Morady F; Scheinman MM; Hess DS
    Pacing Clin Electrophysiol; 1983 May; 6(3 Pt 1):609-15. PubMed ID: 6191299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation.
    Heger JJ; Prystowsky EN; Zipes DP
    Am Heart J; 1983 Oct; 106(4 Pt 2):887-94. PubMed ID: 6613835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of clinical and subclinical toxicity associated with amiodarone treatment of refractory tachyarrhythmias.
    Anastasiou-Nana MI; Anderson JL; Nanas JN; Lutz JR; Smith RA; Anderson KP; Crapo RO; Call NB
    Can J Cardiol; 1986; 2(3):138-45. PubMed ID: 2941121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
    McGovern B; Garan H; Malacoff RF; DiMarco JP; Grant G; Sellers TD; Ruskin JN
    Am J Cardiol; 1984 Jun; 53(11):1558-63. PubMed ID: 6731300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables.
    DiCarlo LA; Morady F; Sauve MJ; Malone P; Davis JC; Evans-Bell T; Winston SA; Scheinman MM
    Am J Cardiol; 1985 Feb; 55(4):372-4. PubMed ID: 3969871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.
    Heger JJ; Prystowsky EN; Jackman WM; Naccarelli GV; Warfel KA; Rinkenberger RL; Zipes DP
    N Engl J Med; 1981 Sep; 305(10):539-45. PubMed ID: 6789201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone.
    Strasberg B; Kusniec J; Zlotikamien B; Mager A; Sclarovsky S
    Am J Cardiol; 1990 Sep; 66(7):673-8. PubMed ID: 2399883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias.
    Fogoros RN; Anderson KP; Winkle RA; Swerdlow CD; Mason JW
    Circulation; 1983 Jul; 68(1):88-94. PubMed ID: 6851057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal.
    Lavery D; Saksena S
    Am Heart J; 1987 Jan; 113(1):49-56. PubMed ID: 3799441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study.
    Klein LS; Fineberg N; Heger JJ; Miles WM; Kammerling JM; Chang MS; Zipes DP; Prystowsky EN
    Am J Cardiol; 1988 May; 61(13):1024-30. PubMed ID: 3364357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias.
    Greene HL; Graham EL; Werner JA; Sears GK; Gross BW; Gorham JP; Kudenchuk PJ; Trobaugh GB
    J Am Coll Cardiol; 1983 Dec; 2(6):1114-28. PubMed ID: 6685151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease.
    Yazaki Y; Haffajee CI; Gold RL; Bishop RL; Alpert JS
    Am J Cardiol; 1987 Aug; 60(4):293-7. PubMed ID: 3618488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias.
    Kato K
    Ann N Y Acad Sci; 1992 Jan; 644():235-45. PubMed ID: 1562118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia.
    Morady F; Scheinman MM; Shen E; Shapiro W; Sung RJ; DiCarlo L
    Am J Cardiol; 1983 Jan; 51(1):156-9. PubMed ID: 6401373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia.
    Saksena S; Rothbart ST; Shah Y; Cappello G
    Am J Cardiol; 1984 Aug; 54(3):347-52. PubMed ID: 6465016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical follow-up guidelines for patients treated with amiodarone.
    Podrid PJ
    Clin Cardiol; 1987 Jul; 10(7 Suppl 1):I10-6. PubMed ID: 3078154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation.
    Schützenberger W; Leisch F; Kerschner K; Harringer W; Herbinger W
    Br Heart J; 1989 Nov; 62(5):367-71. PubMed ID: 2590589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease.
    Horowitz LN; Greenspan AM; Spielman SR; Webb CR; Morganroth J; Rotmensch H; Sokoloff NM; Rae AP; Segal BL; Kay HR
    Am J Cardiol; 1985 Feb; 55(4):367-71. PubMed ID: 3969870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo).
    Kudenchuk PJ; Leroux BG; Daya M; Rea T; Vaillancourt C; Morrison LJ; Callaway CW; Christenson J; Ornato JP; Dunford JV; Wittwer L; Weisfeldt ML; Aufderheide TP; Vilke GM; Idris AH; Stiell IG; Colella MR; Kayea T; Egan D; Desvigne-Nickens P; Gray P; Gray R; Straight R; Dorian P;
    Circulation; 2017 Nov; 136(22):2119-2131. PubMed ID: 28904070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.